Neogen Chemicals (NEOGEN) Stock Overview
Engages in the manufacture and sale of specialty chemicals in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
NEOGEN Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Neogen Chemicals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,687.10 |
| 52 Week High | ₹1,883.00 |
| 52 Week Low | ₹966.70 |
| Beta | 0.59 |
| 1 Month Change | 11.84% |
| 3 Month Change | 27.17% |
| 1 Year Change | 7.79% |
| 3 Year Change | 11.40% |
| 5 Year Change | 73.37% |
| Change since IPO | 540.14% |
Recent News & Updates
Narrative Update • May 11
NEOGEN: Preferential Equity Funding Will Support Long Term Upside Potential
Analysts have trimmed their price target for Neogen Chemicals from ₹2,630 to about ₹2,311 as they factor in more moderate revenue growth assumptions, a slightly higher profit margin outlook, and a lower future P/E multiple in their models. What's in the News Board meeting scheduled for April 18, 2026, to consider allotment of 1,000,000 equity shares with face value of ₹10 at an issue price of ₹1,610 per share on a preferential basis, aggregating up to ₹1,610,000,000.
Narrative Update • Apr 23
NEOGEN: Equity Fundraising Plans Will Pressure Elevated Future P E Multiple
Analysts have kept their price target for Neogen Chemicals steady at ₹1,335, citing only small refinements to their discount rate, revenue growth outlook and profit margin assumptions, along with a slightly lower future P/E multiple, rather than any major shift in the investment case. What's in the News On February 11, 2026, the board met to review unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025, and to evaluate various options for raising funds through equity and other securities in one or more tranches (company filing).Recent updates
Narrative Update • May 11
NEOGEN: Preferential Equity Funding Will Support Long Term Upside Potential
Analysts have trimmed their price target for Neogen Chemicals from ₹2,630 to about ₹2,311 as they factor in more moderate revenue growth assumptions, a slightly higher profit margin outlook, and a lower future P/E multiple in their models. What's in the News Board meeting scheduled for April 18, 2026, to consider allotment of 1,000,000 equity shares with face value of ₹10 at an issue price of ₹1,610 per share on a preferential basis, aggregating up to ₹1,610,000,000.Narrative Update • Apr 23
NEOGEN: Equity Fundraising Plans Will Pressure Elevated Future P E Multiple
Analysts have kept their price target for Neogen Chemicals steady at ₹1,335, citing only small refinements to their discount rate, revenue growth outlook and profit margin assumptions, along with a slightly lower future P/E multiple, rather than any major shift in the investment case. What's in the News On February 11, 2026, the board met to review unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025, and to evaluate various options for raising funds through equity and other securities in one or more tranches (company filing).Narrative Update • Apr 09
NEOGEN: Future PE Reset Will Test Sustainability Of Recent Cost Improvements
Narrative Update Analysts have held the fair value estimate for Neogen Chemicals steady at ₹1,335.00 while updating assumptions on growth, margins and future P/E. This reflects recent research that cites stronger revenue and EBITDA performance, cost actions taking hold and higher external price targets in the range of roughly ₹540 to ₹1,000 equivalent.
Narrative Update • Mar 25
NEOGEN: Raised Guidance And Cost Actions Will Support Higher Future Earnings Quality
Narrative Update Overview The revised analyst price target for Neogen Chemicals edges slightly lower to ₹1,756.25 from ₹1,769.57. This reflects updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while staying broadly aligned with recent Street research that has cited better revenue and EBITDA prints, higher guidance, and early benefits from cost actions.Narrative Update • Mar 10
NEOGEN: Future P E Compression Will Challenge Optimism Around Cost Driven Margin Gains
Our updated fair value estimate for Neogen Chemicals shifts to ₹1,335 from ₹1,670 as analysts factor in slightly adjusted growth assumptions, a modestly lower discount rate, firmer profit margins and a reduced future P/E multiple, broadly in line with recent Street research that links higher targets in other names to improving revenue quality, cost actions and guidance. Analyst Commentary Street research around Neogen Chemicals points to a more measured setup, even as some peers in the sector see higher optimism baked into targets.Narrative Update • Feb 24
NEOGEN: Raised Guidance And Cost Actions Will Support Richer Future Earnings Multiple
Analysts have trimmed their fair value estimate for Neogen Chemicals from ₹1,847 to about ₹1,770, as slightly softer revenue growth and margin inputs are being offset by a higher assumed future P/E multiple and recent Street target hikes following better than expected earnings and guidance. Analyst Commentary Recent Street research around Neogen Chemicals reflects a mix of optimism about execution and some caution on how durable the current momentum might be for earnings and valuation.Narrative Update • Feb 10
NEOGEN: Raised Guidance And Cost Actions Will Support Further Upside
Narrative Update: Neogen Chemicals Analysts have lifted their price target on Neogen Chemicals to a range of about $10 to $12, up from $6.50 to $8. This change is attributed to the company’s recent revenue and EBITDA beat, raised guidance, and early benefits from portfolio execution and cost actions.Narrative Update • Jan 26
NEOGEN: Raised Guidance And Upcoming Board Results Will Support Upside
Narrative Update The analyst price target for Neogen Chemicals has been adjusted from approximately ₹1,812 to ₹1,847 as analysts factor in recent research that points to steady fair value assumptions, a slightly higher discount rate, unchanged growth and margin inputs, and a modestly higher future P/E multiple in light of recent earnings commentary and guidance updates on Neogen. Analyst Commentary Recent Street research on Neogen Chemicals highlights a mix of optimism around execution and guidance, paired with some restraint on how far the valuation should stretch after the latest earnings release.Narrative Update • Jan 09
NEOGEN: Steady Fair Value And Upcoming Results Will Support Upside
Analysts have kept their fair value estimate for Neogen Chemicals steady at ₹1,812.29 per share, with only marginal adjustments to the discount rate, revenue growth, profit margin and future P/E inputs that are too small to materially change the target at this time. What's in the News Board meeting scheduled for November 8, 2025, at 14:30 Indian Standard Time to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Narrative Update • Dec 26
NEOGEN: Market Perform Initiation Will Support Upside From Resilient Margins
Analysts have modestly revised their price target on Neogen Chemicals upward to $10, reflecting slightly higher long term growth expectations and largely stable margin and valuation assumptions. Analyst Commentary The latest initiation at a Market Perform rating with a $10 price target highlights a balanced view on Neogen Chemicals, with analysts seeing the current valuation as broadly aligned with its near to medium term growth prospects.Narrative Update • Dec 11
NEOGEN: Market Perform Initiation Will Support Steady Future Return Potential
Analysts have nudged their price target for Neogen Chemicals slightly higher, reflecting a modest improvement in fair value to roughly ₹1,812 per share. This is supported by expectations of sustained high revenue growth and stable valuation multiples, despite only minor adjustments to discount rate and profit margin assumptions.Analysis Article • Dec 04
Why We're Not Concerned Yet About Neogen Chemicals Limited's (NSE:NEOGEN) 26% Share Price Plunge
The Neogen Chemicals Limited ( NSE:NEOGEN ) share price has fared very poorly over the last month, falling by a...Narrative Update • Nov 27
NEOGEN: Broader Customer Base And Joint Venture Will Support Steady Future Returns
Analysts have maintained Neogen Chemicals' price target at $1,806.57, citing stable growth expectations and aligning their assessment with the recent initiation of a Market Perform rating by the Street. Analyst Commentary Bullish Takeaways Bullish analysts note Neogen Chemicals' consistent revenue growth, which supports the current valuation and underpins the stable price target.Analysis Article • Nov 16
We Think That There Are More Issues For Neogen Chemicals (NSE:NEOGEN) Than Just Sluggish Earnings
Neogen Chemicals Limited's ( NSE:NEOGEN ) earnings announcement last week contained some soft numbers, disappointing...Analysis Article • Nov 14
Analysts Are More Bearish On Neogen Chemicals Limited (NSE:NEOGEN) Than They Used To Be
One thing we could say about the analysts on Neogen Chemicals Limited ( NSE:NEOGEN ) - they aren't optimistic, having...Narrative Update • Nov 12
NEOGEN: Product Diversification Will Drive Long-Term Returns After New Joint Venture
Analysts have revised Neogen Chemicals' fair value target downward from ₹2,062.83 to ₹1,806.57. This adjustment is due to a slightly higher discount rate and moderated revenue growth expectations, as reflected in recent research updates.Analysis Article • Nov 11
These 4 Measures Indicate That Neogen Chemicals (NSE:NEOGEN) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Narrative Update • Aug 06
Expanding Lithium Battery Materials Will Secure Global Reach
Despite an upward revision in revenue growth forecasts, Neogen Chemicals’ consensus price target has been lowered to ₹2,062, primarily due to a substantial decline in its future P/E multiple. What's in the News Annual dividend decreased to INR 1 per share for FY 2024-25.
New Narrative • Mar 15
Merger With BuLi Chemicals Will Strengthen Market Position In Pharma And Agrochemicals
The merger and strategic product expansions aim to strengthen Neogen's market position and boost future export and domestic revenue growth.Analysis Article • Feb 21
Neogen Chemicals Limited's (NSE:NEOGEN) P/S Is On The Mark
When you see that almost half of the companies in the Chemicals industry in India have price-to-sales ratios (or "P/S...Analysis Article • Feb 06
Neogen Chemicals Limited Just Missed Earnings - But Analysts Have Updated Their Models
It's been a pretty great week for Neogen Chemicals Limited ( NSE:NEOGEN ) shareholders, with its shares surging 16% to...Analysis Article • Dec 26
Here's Why Neogen Chemicals (NSE:NEOGEN) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Dec 10
The Returns On Capital At Neogen Chemicals (NSE:NEOGEN) Don't Inspire Confidence
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...Analysis Article • Nov 20
Why Neogen Chemicals' (NSE:NEOGEN) Shaky Earnings Are Just The Beginning Of Its Problems
A lackluster earnings announcement from Neogen Chemicals Limited ( NSE:NEOGEN ) last week didn't sink the stock price...Analysis Article • Nov 16
Earnings Miss: Neogen Chemicals Limited Missed EPS By 6.7% And Analysts Are Revising Their Forecasts
Last week, you might have seen that Neogen Chemicals Limited ( NSE:NEOGEN ) released its second-quarter result to the...Analysis Article • Sep 20
Investors Appear Satisfied With Neogen Chemicals Limited's (NSE:NEOGEN) Prospects As Shares Rocket 36%
The Neogen Chemicals Limited ( NSE:NEOGEN ) share price has done very well over the last month, posting an excellent...Analysis Article • May 08
We Think That There Are More Issues For Neogen Chemicals (NSE:NEOGEN) Than Just Sluggish Earnings
Neogen Chemicals Limited's ( NSE:NEOGEN ) recent weak earnings report didn't cause a big stock movement. We think that...Analysis Article • May 05
Earnings Miss: Neogen Chemicals Limited Missed EPS By 24% And Analysts Are Revising Their Forecasts
As you might know, Neogen Chemicals Limited ( NSE:NEOGEN ) last week released its latest full-year, and things did not...Analysis Article • Apr 26
After Leaping 27% Neogen Chemicals Limited (NSE:NEOGEN) Shares Are Not Flying Under The Radar
Neogen Chemicals Limited ( NSE:NEOGEN ) shares have had a really impressive month, gaining 27% after a shaky period...Analysis Article • Apr 12
Are Neogen Chemicals Limited (NSE:NEOGEN) Investors Paying Above The Intrinsic Value?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Neogen Chemicals fair value estimate is ₹1,238 Current share...Analysis Article • Aug 11
Neogen Chemicals (NSE:NEOGEN) Is Increasing Its Dividend To ₹2.75
Neogen Chemicals Limited's ( NSE:NEOGEN ) dividend will be increasing from last year's payment of the same period to...Shareholder Returns
| NEOGEN | IN Chemicals | IN Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | 0.5% |
| 1Y | 7.8% | -2.6% | -0.7% |
Return vs Industry: NEOGEN exceeded the Indian Chemicals industry which returned -2.6% over the past year.
Return vs Market: NEOGEN exceeded the Indian Market which returned -0.7% over the past year.
Price Volatility
| NEOGEN volatility | |
|---|---|
| NEOGEN Average Weekly Movement | 8.7% |
| Chemicals Industry Average Movement | 7.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.8% |
Stable Share Price: NEOGEN's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: NEOGEN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 779 | Harin Kanani | www.neogenchem.com |
Neogen Chemicals Limited engages in the manufacture and sale of specialty chemicals in India. It offers organo bromine compounds, such as alkyl bromide compounds, dibromoalkane compounds, bromo chloro alkanes, bromine derivatives of organoacids, bromoacid ester compounds, aromatic bromine derivatives, cyclic bromine derivatives, and speciality bromo fluro derivatives; speciality chloro compounds comprising unsaturated bromine derivatives, bromo hydroxy derivatives, and other compounds; and organo lithium compounds, including n-butyl lithium, lithium hexamethyldisilazide, lithium tetrahydride borate, lithium diisopropylamide, lithium tri-(t-butoxy) aluminium hydride, hexyl lithium, methyl lithium, and phenyl lithium. The company also provides inorganic chemicals comprising inorganic bromine compounds and lithium salts; grignard reagents; advance intermediates; and chemistries, such as alkylation, amination, oxidation, dehalogenation, silylation, anhydrous HF and HBr reactions, suzuki coupling, hydrogenation, and biocatalysis.
Neogen Chemicals Limited Fundamentals Summary
| NEOGEN fundamental statistics | |
|---|---|
| Market cap | ₹46.20b |
| Earnings (TTM) | ₹287.50m |
| Revenue (TTM) | ₹8.68b |
160.7x
P/E Ratio5.3x
P/S RatioIs NEOGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEOGEN income statement (TTM) | |
|---|---|
| Revenue | ₹8.68b |
| Cost of Revenue | ₹4.66b |
| Gross Profit | ₹4.02b |
| Other Expenses | ₹3.73b |
| Earnings | ₹287.50m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.50 |
| Gross Margin | 46.27% |
| Net Profit Margin | 3.31% |
| Debt/Equity Ratio | 162.9% |
How did NEOGEN perform over the long term?
See historical performance and comparisonDividends
0.06%
Current Dividend Yield8%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/21 02:32 |
| End of Day Share Price | 2026/05/21 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neogen Chemicals Limited is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| null null | Asian Markets Securities Private Limited |
| Vijayaraghavan Swaminathan | Avendus Spark |